US Patent Issued to Astellas Pharma on Aug. 12 for "Quinazoline compound for inducing degradation of G12D mutant KRAS protein" (Japanese Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,794, issued on Aug. 12, was assigned to Astellas Pharma Inc. (Tokyo).

"Quinazoline compound for inducing degradation of G12D mutant KRAS protein" was invented by Tomohiro Yoshinari (Tokyo), Hiroki Ishioka (Tokyo), Eiji Kawaminami (Tokyo), Hideyuki Watanabe (Tokyo), Kenichi Kawaguchi (Tokyo), Kazuyuki Kuramoto (Tokyo), Tomoyoshi Imaizumi (Tokyo), Takahiro Morikawa (Tokyo), Hisao Hamaguchi (Tokyo), Sunao Imada (Tokyo), Mitsuaki Okumura (Tokyo), Takeyuki Nagashima (Tokyo) and Kohei Inamura (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pan...